Protherics is a vertically integrated biotechnology company focused on developing and marketing oncology and critical care products. The company is one of the first United Kingdom biotechnology companies to develop and manufacture two biopharmaceutical products to the regulatory approval of the Food and Drug Administration in the United States. Protherics plans to develop a balanced pipeline of products. The company seeks to use industry collaborations to achieve goals in an industry where critical mass is needed to achieve growth. Protherics also gains income from activities, such as licensing revenues from a Bovine Spongiform Encephalopathy (mad cow disease) test sold by Enfer Scientific and its distribution partner Abbott Laboratories; sales of ViperaTAb for the treatment of bites from the European Viper in Scandinavia; and sales in Europe of Voraxaze, a recombinant enzyme designed to break down methotrexate in cancer patients who are experiencing toxicity. Protherics is located in Brentwood, Tenn.